{"id":"W3164781831","doi":"10.1016/s1470-2045(21)00147-9","title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":533,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Pharmaceuticals; Pfizer Japan; Genentech; Bavarian Nordic; Merck Sharp and Dohme; Ono Pharmaceutical; European Association of Urology; Bayer Fund; Mirati Therapeutics; Clovis Oncology; Sanofi; GlaxoSmithKline; Merck; Genzyme; Genomic Health; Chugai Pharmaceutical; Roche; Astellas Pharma US; Pfizer; Heron Therapeutics; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Cystoscopy; Bladder cancer; Cystectomy; Cancer; Internal medicine; Clinical endpoint; Surgery; Progressive disease; Urology; Oncology; Clinical trial; Immunotherapy; Disease; Urinary system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003211092,0.0003863735,0.001227535,0.00006992641,0.0003236888,0.00004941225,0.0005185082,0.0001335987,0.0003679892],"category_scores_gemma":[0.0001477278,0.0002166905,0.0001096897,0.0003290406,0.0001480589,0.00008540498,0.0001028502,0.0001760501,0.00001938928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007021311,"about_ca_system_score_gemma":0.001190643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005355675,"about_ca_topic_score_gemma":0.01083279,"domain_scores_codex":[0.997413,0.0006123316,0.0004641006,0.0006478565,0.000265525,0.0005971756],"domain_scores_gemma":[0.9963145,0.001525251,0.0002913601,0.001208396,0.00045515,0.0002052965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1147223,0.09657296,0.003440816,0.00007114328,0.007795713,0.0006400418,0.05264287,0.0004623357,0.03232995,0.0001742325,0.005419781,0.6857278],"study_design_scores_gemma":[0.4186711,0.3097703,0.03657388,0.0001593661,0.008200466,0.0001123541,0.01712411,0.0005340608,0.07832822,0.0007109439,0.1290085,0.0008066364],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9795064,0.001823792,0.0003423057,0.009373995,0.0007428222,0.006996357,0.000711795,0.00004205373,0.0004604525],"genre_scores_gemma":[0.9851564,0.003672328,0.001667045,0.004390954,0.001134051,0.002714235,0.00005911144,0.00008251458,0.00112333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6849212,"threshold_uncertainty_score":0.8836381,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1191642110718247,"score_gpt":0.4364849762544737,"score_spread":0.3173207651826491,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}